RE:RE:“Highly likely to succeed”I agree.
But this may have to be an FDA decision/request.
And...another consideration. The ARR (absolute risk reduction) is likely to increase (on average) with each new patient. This is becasue they have a better targeted patient popultion in Tigris, based on everything they have learned in Phase 3. The final stats are an amalgum of Euprates 179 and Tigris 150.
The higher the ARR perhaps the higher the price that the treatment might command once commecialization begins.
e.g. Spectral assumed $ 6750 per column in their latest EBITDA analysis
Paradigm assumes $ 7750 per column in their discounted cashflow model
Maybe at 25-30% the price could be $8750? or more?
as an example $ 8750 is 30% higher revenues than $ 6750
Now add in extra columns for some patients (studies have shown improved outcomes for > 2 columns for some patients.). Will EDEN shed light on this?